Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma

Journal of Clinical Microbiology

Volumn 35, Issue 11, 1997, Pages 2886-2893

  Ginocchio, Christine C ^a   Wang, Xue Ping ^a   Kaplan, Mark H ^a   Mulligan, Gaby ^a   Witt, Donald ^b   Romano, Joseph W ^c   Cronin, Michael ^b   Carroll, Richard ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b Organon Teknika Corporation   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA ANALYSIS; VIRUS TYPING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0030763603     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.35.11.2886-2893.1997     Document Type: Article

References (28)

1. Bagnarelli, P., S. Menzo, A. Valenza, S. Poalucci, S. Petroni, G. Scalise, R. Sampaolesi, A. Manzin, P. E. Varaldo, and M. Clement. 1995. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J. Clin. Microbiol. 33: 16-23.
2. Collier, A. C., R. W. Coombs, M. A. Fischl, P. R. Skolnik, D. Northfeldt, P. Boutin, C. J. Hooper, L. D. Kaplan, P. A. Volberding, L. G. Davis, D. R. Henrard, S. Weller, and L. Corey. 1993. Combination therapy with zidovudine and didanosine compared to zidovudine alone in human immunodeficiency virus type one infection. Ann. Intern. Med. 119:786-793.
3. Coombs, R. W., D. R. Henrard, W. F. Mehaffey, J. Gibson, E. Eggert, T. C. Quinn, and J. Phillips. 1993. Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J. Clin. Microbiol. 31:1980-1986.
4. Coombs, R. W. 1994. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS. Clin. Lab. Med. 14:301-311.
5. Coombs, R. W., S. L. Welles, C. Hooper, P. S. Reichelderfer, R. T. D'Aquila, A. J. Japoyr, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, S. Kwok, J. Todd, J. B. Jackson, V. De Gruttola, C. S. Crumpacker, and J. Kahn. 1996. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. 174:704-712.
6. Cunningham, A. L., D. E. Dwyer, and D. N. Dowton. 1993. Viral markers in HIV infection and AIDS. J. Acquired Immune Defic. Syndr. 6(Suppl. 1): S32-S35.
7. Ho, D. D., A. U. Neuman, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
8. Hogervost, E., S. Jurriaans, F. de Wolf, A. van Wijk, A. Wiersma, M. Valk, M. Roos, D. van Gemen, R. Coutinho, F. Miedema, and J. Goudsmit. 1995. Predictors for non-and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J. Infect. Dis. 171:811-821.
9. Holodniy, M., D. A. Katzenstein, D. M. Israelski, and T. C. Merigan. 1991. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J. Clin. Invest. 88:1755-1759.
10. Holodniy, M., S. Kim, D. A. Katzenstein, M. Konrad, E. Groves, and T. C. Merigan. 1991. Inhibition of human immunodeficiency virus gene amplification by heparin. J. Clin. Microbiol. 29:676-679.
11. Holodniy, M., D. A. Katzenstein, M. A. Winters, J. Montoya, R. Shafer, M. Kozal, M. Ragni, and T. C. Merigan. 1993. Gene amplification techniques to measure viral load and genotypic resistance in asymptomatic subjects treated with combination therapy. J. Acquired Immune Defic. Syndr. 6:366-369.
12. Holodniy, M., L. Mole, R. Carroll, and J. Todd. 1994. Virion HIV RNA in plasma does not appear to be platelet associated, abstr. 2040. In Programs and Abstracts of the Tenth International Conference on AIDS, Yokohama, Japan, 1994.
13. Holodniy, M., L. Mole, B. Yen-Lieberman, D. Margolis, C. Starkey, R. Carroll, T. Spahlinger, J. Todd, and J. B. Jackson. 1995. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J. Clin. Microbiol. 33:1562-1566.
14. Jurriaans, S., B. van Gemen, G. J. Weverling, D. van Strijp, P. Nara, R. Coutinho, M. Koot, H. Schuitemaker, and J. Goudsmit. 1994. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 204:223-233.
15. Klebanoff, S. J., and R. W. Coombs. 1992. Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. J. Clin. Invest. 89: 2014-2017.
16. Lee, T. H., R. R. Stromberg, D. Henrard, and M. Busch. 1993. Effect of platelet-associated virus on HIV-1 in plasma. Science 262:1585-1586.
17. Mellors, J. W., L. A. Kingsley, C. R. Rinaldo, J. A. Todd, B. S. Hoo, R. Kokka, and P. Gupta. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
18. Mole, L., D. Margols, R. Carroll, J. Todd, and M. Holodniy. 1994. Stability of quantitative human immunodeficiency virus plasma culture, RNA, and p24 antigen from samples collected in VACUTAINER CPT versus standard VACUTAINER tubes. J. Clin. Microbiol. 32:2212-2215.
19. Moudgil, T., and E. S. Daar. 1993. Infectious decay of human immunodeficiency virus type 1 in plasma. J. Infect. Dis. 167:210-212.
20. O'Brien, W. A., P. M. Hartigan, D. Martin, J. Esinhart, A. Hill, S. Benoit, M. Rubin, M. S. Simberkoff, J. D. Hamilton, et al. 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426-431.
21. O'Shea, S., T. Rostron, J. E. Mullen, and J. E. Banatvala. 1994. Stability of infectious HIV in clinical samples and isolation from small samples of whole blood. J. Clin. Pathol. 47:152-154.
22. Pachl, C., J. A. Todd, D. G. Kern, P. J. Sheridan, S. J. Fong, M. Stempien, B. Hoo, D. Besemer, T. Yeghiazarian, B. Irvine, J. Kolberg, R. Kokka, P. Neuwald, and M. S. Urdea. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquired Immune Defic. Syndr. 8:446-454.
23. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K.-C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifsno. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
24. Urdea, M. 1993. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clin. Chem. 39:725-726.
25. Vandamme, A. M., J. C. Schmit, S. Van Dooren, K. Van Laethem, E. Gobbers, W. Kok, P. Goubu, M. Witvrouw, W. Peetermans, E. De Clercq, and J. Desmyter. 1996. Quantitation of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV Monitor test. J. Acquired Immune Defic. Syndr. 13:127-139.
26. van Gemen, B., R. van Beuningen, A. Nabbe, D. van Strijp, S. Jurriaans, P. Lens, and T. Kievits. 1994. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescence (ECL) labelled probes. J. Virol. Methods 49:157-168.
27. van Gemen, B., P. V. D. Wiel, R. van Beuningen, P. Sillekens, S. Jurriaans, C. Dries, R. Schoones, and T. Kievits. 1995. The one-tube quantitative HIV-1 RNA NASBA: precision, accuracy, and application. PCR Methods Appl. 4:S177-S184.
28. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emmini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.